Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Stock Information for Palladyne AI Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Palladyne AI Corp.

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Coherus to Participate in Upcoming Investor Conferences
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.